From Methylomes to CRISPR Epigenetic Editing: New Paths in Antibiotic Resistance
Pathogens · 2025
DOI: 10.3390/pathogens14121267 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pathogens, 2025. Verfasst von Nada M Nass und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia. Hauptthemen laut MEDLINE: Gene Editing, Epigenesis, Genetic, Bacteria, CRISPR-Cas Systems. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Antibiotic resistance (AR) has long been interpreted through the lens of genetic mutations and horizontal gene transfer. Yet, mounting evidence suggests that epigenetic regulation, including DNA and RNA methylation, histone-like proteins, and small non-coding RNAs, plays a similarly critical role in bacterial adaptability. These reversible modifications reshape gene expression without altering the DNA sequence, enabling transient resistance, phenotypic heterogeneity, and biofilm persistence under antimicrobial stress. Advances in single-molecule sequencing and methylome mapping have uncovered diverse DNA methyltransferase systems that coordinate virulence, efflux, and stress responses. Such epigenetic circuits allow pathogens to survive antibiotic exposure, then revert to susceptibility once pressure subsides, complicating clinical treatment. Parallel advances in CRISPR-based technologies now enable direct manipulation of these regulatory layers. CRISPR interference (CRISPRi) and catalytically inactive dCas9-fused methyltransferases can silence or reactivate genes in a programmable, non-mutational manner, offering a new route to reverse resistance or sensitize pathogens. Integrating methylomic data with transcriptomic and proteomic profiles further reveals how epigenetic plasticity sustains antimicrobial tolerance across environments. This review traces the continuum from natural bacterial methylomes to engineered CRISPR-mediated epigenetic editing, outlining how this emerging interface could redefine antibiotic stewardship. Understanding and targeting these reversible, heritable mechanisms opens the door to precision antimicrobial strategies that restore the effectiveness of existing drugs while curbing the evolution of resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
- Immunology Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
- Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
ORCID-Profile: Nada M Nass, Kawther A Zaher
Zitieren
APA
Nass, N. M., & Zaher, K. A. (2025). From Methylomes to CRISPR Epigenetic Editing: New Paths in Antibiotic Resistance. Pathogens. https://doi.org/10.3390/pathogens14121267
Vancouver
Nass NM, Zaher KA. From Methylomes to CRISPR Epigenetic Editing: New Paths in Antibiotic Resistance. Pathogens. 2025. doi:10.3390/pathogens14121267
BibTeX
@article{Nass2025,
author = {Nass, Nada M and Zaher, Kawther A},
title = {From Methylomes to CRISPR Epigenetic Editing: New Paths in Antibiotic Resistance},
journal = {Pathogens},
year = {2025},
doi = {10.3390/pathogens14121267}
}
EUVIMED